MXPA02002251A - Diagnosticos y terapeuticos para osteoporosis. - Google Patents

Diagnosticos y terapeuticos para osteoporosis.

Info

Publication number
MXPA02002251A
MXPA02002251A MXPA02002251A MXPA02002251A MXPA02002251A MX PA02002251 A MXPA02002251 A MX PA02002251A MX PA02002251 A MXPA02002251 A MX PA02002251A MX PA02002251 A MXPA02002251 A MX PA02002251A MX PA02002251 A MXPA02002251 A MX PA02002251A
Authority
MX
Mexico
Prior art keywords
osteoporosis
therapeutics
diagnostics
identification
subject
Prior art date
Application number
MXPA02002251A
Other languages
English (en)
Spanish (es)
Inventor
Van Dijk Simon
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of MXPA02002251A publication Critical patent/MXPA02002251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02002251A 1999-08-30 2000-08-30 Diagnosticos y terapeuticos para osteoporosis. MXPA02002251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15146099P 1999-08-30 1999-08-30
PCT/US2000/023844 WO2001016377A2 (en) 1999-08-30 2000-08-30 Diagnostics and therapeutics for osteoporosis

Publications (1)

Publication Number Publication Date
MXPA02002251A true MXPA02002251A (es) 2003-08-20

Family

ID=22538869

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002251A MXPA02002251A (es) 1999-08-30 2000-08-30 Diagnosticos y terapeuticos para osteoporosis.

Country Status (11)

Country Link
US (2) US6558905B1 (enExample)
EP (1) EP1212464B1 (enExample)
JP (1) JP2004504802A (enExample)
AT (1) ATE318328T1 (enExample)
AU (2) AU785040B2 (enExample)
BR (1) BR0014150A (enExample)
CA (1) CA2382848C (enExample)
DE (1) DE60026150T2 (enExample)
ES (1) ES2261239T3 (enExample)
MX (1) MXPA02002251A (enExample)
WO (1) WO2001016377A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508022A (ja) * 1999-06-30 2003-03-04 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法
US20090023147A1 (en) * 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
JP2005500032A (ja) * 2001-06-15 2005-01-06 インターリューキン ジェネティックス インコーポレイテッド 老化関連症状の早期発現を検出および治療する方法
TWI346700B (en) * 2002-01-25 2011-08-11 Interleukin Genetics Inc The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU2003265676A1 (en) * 2002-08-24 2004-03-11 Creighton University Methods for detecting genes associated with bone properties and/or height
JP2006516196A (ja) * 2003-01-16 2006-06-29 デコード ジェネティクス イーエッチエフ． ハプロタイプ関連に基づく、骨粗鬆症または骨粗鬆症に対する罹患性の診断方法
DE602004030367D1 (de) 2003-08-08 2011-01-13 Interleukin Genetics Inc Diagnostikum für osteoporose
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2271827C1 (ru) * 2004-09-28 2006-03-20 Федеральное государственное учреждение"Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Федерального агенства по здравоохранению и социальному развитию"(ФГУ "СПбНИИ ЛОР Росздрава") Способ определения тактики лечения рекомбинантным цитокином, регулирующим воспаление
US7353662B2 (en) * 2004-12-22 2008-04-08 York International Corporation Medium voltage starter for a chiller unit
US8590329B2 (en) 2004-12-22 2013-11-26 Johnson Controls Technology Company Medium voltage power controller
US8105775B2 (en) * 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US8101360B2 (en) * 2006-11-15 2012-01-24 Interleukin Genetics, Inc. IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
CA1316520C (en) 1987-05-19 1993-04-20 Larry C. Hamilton Valve
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1993011149A1 (en) 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
WO1994003633A1 (en) 1992-07-31 1994-02-17 Garvan Institute Of Medical Research Assessment of trans-acting factors allelic variation
DE69333641T2 (de) 1992-12-28 2005-11-03 Baylink, David Jeston, Redlands Methode zur messung der knochenresorption
IL108947A0 (en) 1993-03-12 1994-06-24 Osteopharm Ltd Bone stimulating factor
CA2164498C (en) 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
GB9706359D0 (en) * 1997-03-27 1997-05-14 Gemini International Holdings Polymorphisms of an il-1 receptor antagonist gene
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease

Also Published As

Publication number Publication date
AU2006203097A1 (en) 2006-08-17
AU785040B2 (en) 2006-08-31
EP1212464B1 (en) 2006-02-22
ES2261239T3 (es) 2006-11-16
WO2001016377A2 (en) 2001-03-08
US20040110168A1 (en) 2004-06-10
AU2006203097B2 (en) 2009-03-12
WO2001016377A3 (en) 2002-01-17
US6558905B1 (en) 2003-05-06
CA2382848C (en) 2011-01-04
DE60026150D1 (de) 2006-04-27
ATE318328T1 (de) 2006-03-15
JP2004504802A (ja) 2004-02-19
AU7338000A (en) 2001-03-26
EP1212464A2 (en) 2002-06-12
DE60026150T2 (de) 2006-11-16
CA2382848A1 (en) 2001-03-08
BR0014150A (pt) 2002-05-14

Similar Documents

Publication Publication Date Title
MXPA02002251A (es) Diagnosticos y terapeuticos para osteoporosis.
EP1439796B8 (en) Areal implant
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
MXPA04004939A (es) 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3-alquilados y 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3,3??-dialquilados y procesos para su fabricacion.
ZA991272B (en) Novel thiobenzamides.
ZA995806B (en) Integrated direct reduction iron system.
ZA200005786B (en) Dragline rigging system.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA989536B (en) Medical face mask.
ZA994918B (en) New ketones.
ZA200001456B (en) Transaction apparatus.
ZA993123B (en) Trisresorcinyltriazines.
FI971318A7 (fi) Menetelmä välituotteen valmistamiseksi, joka on hyödyllinen jodattujen varjoaineiden synteesissä
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ZA200307850B (en) Process and system for the removal of scale build-up.
WO2002072883A3 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
MXPA03007242A (es) Delta-1-pirrolinas para control de pestes.
ZA996936B (en) Railbreak indicating arrangement.
GB9827270D0 (en) G.c.t.s.
ZA983781B (en) Process for the preparation of 1,1,1,3,3-pentachlorobutane.
UA2519S (uk) Садово - паркова лава системи в. к. чернова